Calpastatin overexpression in the skeletal muscle of mice prevents clenbuterol-induced muscle hypertrophy and phenotypic shift

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 4, 2012, Pages 364-372

  Douillard, Aymeric ^a   Galbes, Olivier ^a   Begue, Gwenaelle ^a   Rossano, Bernadette ^a   Levin, John ^a   Vernus, Barbara ^a   Bonnieu, Anne ^a   Candau, Robin ^a   Py, Guillaume ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

Calpain; Calpastatin; Clenbuterol; Hypertrophy; Mouse; Muscle; Phenotypic shift

Indexed keywords

AMPK PROTEIN; CALPAIN; CALPASTATIN; CAMK2 PROTEIN; CLENBUTEROL; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN; PROTEIN KINASE B; PROTEIN S6; UNCLASSIFIED DRUG;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ELECTROPORATION; EXPRESSION VECTOR; GENE OVEREXPRESSION; MALE; MOUSE; MUSCLE HYPERTROPHY; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SKELETAL MUSCLE; TIBIALIS ANTERIOR MUSCLE;

ANIMALS; CALCIUM-BINDING PROTEINS; CALPAIN; CATTLE; CLENBUTEROL; GENE EXPRESSION REGULATION; HYPERTROPHY; MALE; MICE; MICE, INBRED CBA; MUSCLE, SKELETAL; PHENOTYPE;

EID: 84858987556     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2012.05677.x     Document Type: Article

References (39)

1. 2+-dependent proteinases (mu-calpain and m-calpain). J. Biol. Chem. 1989; 264: 10096-103.
2. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol. Rev. 2003; 83: 731-801.
3. Davies PJ, Wallach D, Willingham MC, Pastan I, Yamaguchi M, Robson RM. Filamin-actin interaction. Dissociation of binding from gelation by Ca2 + -activated proteolysis. J. Biol. Chem. 1978; 253: 4036-42.
4. 2+-activated protease possibly involved in myofibrillar protein turnover. Purification from porcine muscle. Biochemistry 1976; 15: 2150-8.
5. Goll DE, Neti G, Mares SW, Thompson VF. Myofibrillar protein turnover: The proteasome and the calpains. J. Anim. Sci. 2008; 86: E19-35.
6. Kawasaki H, Emori Y, Suzuki K. Calpastatin has two distinct sites for interaction with calpain: Effect of calpastatin fragments on the binding of calpain to membranes. Arch. Biochem. Biophys. 1993; 305: 467-72.
7. Sultan KR, Dittrich BT, Pette D. Calpain activity in fast, slow, transforming, and regenerating skeletal muscles of rat. Am. J. Physiol. Cell Physiol. 2000; 279: C639-47.
8. 2+-activated and ATP-ubiquitin-dependent proteinases in the unweighted rat soleus muscle. Biochem. J 1996; 316: 65-72.
9. Vermaelen M, Sirvent P, Raynaud F et al. Differential localization of autolyzed calpains 1 and 2 in slow and fast skeletal muscles in the early phase of atrophy. Am. J. Physiol. Cell Physiol. 2007; 292: C1723-31.
10. Otani K, Han DH, Ford EL et al. Calpain system regulates muscle mass and glucose transporter GLUT4 turnover. J. Biol. Chem. 2004; 279: 20.
11. Otani K, Polonsky KS, Holloszy JO, Han DH. Inhibition of calpain results in impaired contraction-stimulated GLUT4 translocation in skeletal muscle. Am. J. Physiol. Endocrinol. Metab 2006; 291: E544-8.
12. Gwinn DM, Shackelford DB, Egan DF et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 2008; 30: 214-26.
13. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002; 4: 648-57.
14. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-84.
15. 2+/calmodulin-dependent kinases in skeletal muscle plasticity. J. Appl. Physiol. 2005; 99: 414-23.
16. Chin ER. The role of calcium and calcium/calmodulin-dependent kinases in skeletal muscle plasticity and mitochondrial biogenesis. Proc. Nutr. Soc 2004; 63: 279-86.
17. Lynch GS, Hayes A, Campbell SP, Williams DA. Effects of beta 2-agonist administration and exercise on contractile activation of skeletal muscle fibers. J. Appl. Physiol. 1996; 81: 1610-18.
18. Ryall JG, Plant DR, Gregorevic P, Sillence MN, Lynch GS. Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats. J. Physiol. 2004; 555: 175-88.
19. Bricout VA, Serrurier BD, Bigard AX. Clenbuterol treatment affects myosin heavy chain isoforms and MyoD content similarly in intact and regenerated soleus muscles. Acta Physiol. Scand. 2004; 180: 271-80.
20. Lynch GS, Ryall JG. Role of beta-adrenoceptor signaling in skeletal muscle. Implications for muscle wasting and disease. Physiol. Rev. 2008; 88: 729-67.
21. Bardsley RG, Allcock SM, Dawson JM et al. Effect of beta-agonists on expression of calpain and calpastatin activity in skeletal muscle. Biochimie 1992; 74: 267-73.
22. Parr T, Bardsley RG, Gilmour RS, Buttery PJ. Changes in calpain and calpastatin mRNA induced by beta-adrenergic stimulation of bovine skeletal muscle. Eur. J. Biochem. 1992; 208: 333-9.
23. Douillard A, Galbes O, Rossano B et al. Time course in calpain activity and autolysis in slow and fast skeletal muscle during clenbuterol treatment. Can. J. Physiol. Pharmacol. 2011; 89: 117-25.
24. Bakker AJ, Head SI, Wareham AC, Stephenson DG. Effect of clenbuterol on sarcoplasmic reticulum function in single skinned mammalian skeletal muscle fibers. Am. J. Physiol. 1998; 274: C1718-26.
25. i regulation in murine skeletal myotubes. Am. J. Physiol. 1999; 276: C1038-45.
26. Glass DJ. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat. Cell Biol. 2003; 5: 87-90.
27. Kline WO, Panaro FJ, Yang H, Bodine SC. Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. J. Appl. Physiol. 2007; 102: 740-7.
28. Awede BL, Thissen JP, Lebacq J. Role of IGF-I and IGFBPs in the changes of mass and phenotype induced in rat soleus muscle by clenbuterol. Am. J. Physiol. Endocrinol. Metab 2002; 282: E31-7.
29. Yimlamai T, Dodd SL, Borst SE, Park S. Clenbuterol induces muscle-specific attenuation of atrophy through effects on the ubiquitin-proteasome pathway. J. Appl. Physiol. 2005; 99: 71-80.
30. Burniston JG, Tan LB, Goldspink DF. beta2-Adrenergic receptor stimulation in vivo induces apoptosis in the rat heart and soleus muscle. J. Appl. Physiol. 2005; 98: 1379.86.
31. Deleuze V, Scherman D, Bureau MF. Interleukin-10 expression after intramuscular DNA electrotransfer: Kinetic studies. Biochem. Biophys. Res. Commun. 2002; 299: 29-34.
32. Hoover F, Magne Kalhovde J. A double-injection DNA electroporation protocol to enhance in vivo gene delivery in skeletal muscle. Anal. Biochem. 2000; 285: 175-8.
33. Edelstein CL, Wieder ED, Yaqoob MM et al. The role of cysteine proteases in hypoxia-induced rat renal proximal tubular injury. Proc. Natl Acad. Sci. USA 1995; 92: 7662-6.
34. Carragher NO. Calpain inhibition: A therapeutic strategy targeting multiple disease states. Curr. Pharm. Des. 2006; 12: 615-38.
35. Durieux AC, Bonnefoy R, Freyssenet D. Kinetics of transgene expression after electrotransfer into skeletal muscle: Importance of promoter origin/strength. Biochim. Biophys. Acta 2005; 1725: 403-9.
36. Lantier L, Mounier R, Leclerc J, Pende M, Foretz M, Viollet B. Coordinated maintenance of muscle cell size control by AMP-activated protein kinase. FASEB J 2010; 24: 3555-61.
37. Mounier R, Lantier L, Leclerc J et al. Important role for AMPKalpha1 in limiting skeletal muscle cell hypertrophy. FASEB J 2009; 23: 2264-73.
38. Yang YT, McElligott MA. Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue. Biochem. J 1989; 261: 1-10.
39. Zeman RJ, Ludemann R, Easton TG, Etlinger JD. Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta 2-receptor agonist. Am. J. Physiol. 1988; 254: E726-32.